Neuraxpharm Group announced the establishment of Neuraxpharm Netherlands. The expansion into the Dutch market allows Neuraxpharm to continue on its pathway to becoming the number one CNS specialist in Europe.
Neuraxpharm Netherlands will provide differentiated and specialty generics in the Netherlands, a strategically important CNS pharmaceutical market in Europe. To date, Neuraxpharm Netherlands has launched two products: Dimethyl Fumarate to treat multiple sclerosis and Lacosamide, a product for the treatment of epileptic seizures. In addition, the company plans to launch Rivastagmin for treating dementia, which will become Neuraxpharm's third product in the Netherlands.
The subsidiary will be run by Philipp Pohoralek as Country Manager for Neuraxpharm Netherlands, alongside his current role as Country Manager for Neuraxpharm Germany. As an experienced executive, Philipp will strive to strengthen the company's growth strategy in the Netherlands in line with his achievements in the important German market, which is the third largest CNS market globally. Neuraxpharm Netherlands will conduct its operations from Naarden.
Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, said: "By entering the Dutch market, Neuraxpharm continues its strong growth momentum. We aim to become a leader in the Dutch CNS field, offering high-value-added solutions to our stakeholders and patients. Our aim for 2023 is to further strengthen our portfolio pipeline in the Netherlands and to expand our dedicated team."
Philipp Pohoralek, Country Manager of Neuraxpharm Netherlands, added: "We will leverage our CNS expertise to provide CNS patients, physicians, pharmacists, and hospitals throughout the Netherlands with access to suitable products from our extensive portfolio thereby catering to the needs of patients in the region. We will furthermore provide a tailor-made entry out of more than 120 CNS molecules."
The recent market entry into the Netherlands follows a strong track record. In the past few months, Neuraxpharm has reached several milestones, including entering the Greek CNS market and the steady expansion of its product offering through acquisitions, including two established product portfolios of branded business from Sanofi and prescription brand, Buccolam (midazolam) in 2020, which is indicated for the emergency treatment of children and adolescents with epileptic seizures. In addition, Neuraxpharm has leveraged new business opportunities by entering the digital health and orphan drug markets through new licensing agreements with mjn-SERAS and Minoryx. Finally, the company has reinforced its position as a key player in the European medical cannabis market by creating a business unit dedicated to medical cannabis and expanding its collaboration with Panaxia, a global manufacturer of advanced medical cannabis products, into Switzerland and the Czech Republic.